PMID- 14501719
OWN - NLM
STAT- MEDLINE
DCOM- 20031103
LR  - 20170908
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 170
IP  - 4 Pt 1
DP  - 2003 Oct
TI  - A multicenter clinical trial on the use of complexed prostate specific antigen in 
      low prostate specific antigen concentrations.
PG  - 1175-9
AB  - PURPOSE: The determination of complexed prostate specific antigen (cPSA) has been 
      suggested to be promising for prostate cancer (PCa) diagnosis. In a multicenter 
      trial we evaluate the diagnostic use of PSA forms in the low total PSA (tPSA) 
      range. MATERIALS AND METHODS: A total of 283 white men with and 417 without PCa 
      and tPSA concentrations between 0 and 6 ng/ml were retrospectively analyzed. All 
      700 untreated subjects underwent a multisector needle biopsy of the prostate. The 
      Elecsys analyser 1010 (Roche Diagnostics, Mannheim, Germany) was used for 
      determination of tPSA and free PSA. Determination of cPSA and tPSA was performed 
      using immunoassays of the Bayer Immuno 1 system (Bayer Diagnostics, Tarrytown, 
      New York). RESULTS: Receiver operating characteristics analyses for 
      discrimination between cases with and without PCa were performed. The areas under 
      the curves (AUC) for cPSA, tPSA and free-to-total PSA (f/tPSA) showed no 
      significant differences in the tPSA ranges of 0 to 6 (700 cases), 0 to 4 (510) 
      and 0.5 to 2.5 ng/ml (253). Within the tPSA range of 2.5 to 4 ng/ml (230 cases) 
      the AUC for cPSA (0.61) was significantly larger than that for tPSA (Roche 0.51, 
      Bayer 0.54) but did not differ from the AUC of f/tPSA (Roche). On the basis of 
      the cutoffs for 95% specificity or sensitivity, no significant increase in 
      corresponding sensitivity or specificity was found between tPSA with cPSA. 
      CONCLUSIONS: In the tPSA range of less than 4 ng/ml no improvement in diagnostic 
      accuracy was shown between cPSA with tPSA or the ratio of f/tPSA. The search for 
      a useful marker in the low PSA range must continue.
FAU - Lein, Michael
AU  - Lein M
AD  - Department of Urology, University Hospital Charite, Humboldt University Berlin, 
      Germany. michael.lein@charite.de
FAU - Kwiatkowski, Maciej
AU  - Kwiatkowski M
FAU - Semjonow, Axel
AU  - Semjonow A
FAU - Luboldt, Hans-Joachim
AU  - Luboldt HJ
FAU - Hammerer, Peter
AU  - Hammerer P
FAU - Stephan, Carsten
AU  - Stephan C
FAU - Klevecka, Virgilijus
AU  - Klevecka V
FAU - Taymoorian, Kasra
AU  - Taymoorian K
FAU - Schnorr, Dietmar
AU  - Schnorr D
FAU - Recker, Franz
AU  - Recker F
FAU - Loening, Stefan A
AU  - Loening SA
FAU - Jung, Klaus
AU  - Jung K
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/*analysis
MH  - Prostatic Neoplasms/*diagnosis
MH  - Retrospective Studies
EDAT- 2003/09/23 05:00
MHDA- 2003/11/05 05:00
CRDT- 2003/09/23 05:00
PHST- 2003/09/23 05:00 [pubmed]
PHST- 2003/11/05 05:00 [medline]
PHST- 2003/09/23 05:00 [entrez]
AID - S0022-5347(05)63123-0 [pii]
AID - 10.1097/01.ju.0000087560.30497.4e [doi]
PST - ppublish
SO  - J Urol. 2003 Oct;170(4 Pt 1):1175-9. doi: 10.1097/01.ju.0000087560.30497.4e.